A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC)

Show simple item record

dc.identifier.uri http://dx.doi.org/10.15488/550
dc.identifier.uri http://www.repo.uni-hannover.de/handle/123456789/574
dc.contributor.author Lange, Ansgar
dc.contributor.author Prenzler, Anne
dc.contributor.author Frank, Martin
dc.contributor.author Golpon, Heiko
dc.contributor.author Welte, Tobias
dc.contributor.author Schulenburg, Johann-Matthias Graf von der
dc.date.accessioned 2016-10-28T09:05:31Z
dc.date.available 2016-10-28T09:05:31Z
dc.date.issued 2014
dc.identifier.citation Lange, Angar; Prenzler, Anne; Frank, Martin; Golpon, H.; Welte, T. et al.: A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC). In: BMC Pulmonary Medicine 14(2014), Nr. 1, 192. DOI: http://dx.doi.org/10.1186/1471-2466-14-192
dc.description.abstract Background: Non-small cell lung cancer (NSCLC) imposes a substantial burden on patients, health care systems and society due to increasing incidence and poor survival rates. In recent years, advances in the treatment of metastatic NSCLC have resulted from the introduction of targeted therapies. However, the application of these new agents increases treatment costs considerably. The objective of this article is to review the economic evidence of targeted therapies in metastatic NSCLC. Methods: A systematic literature review was conducted to identify cost-effectiveness (CE) as well as cost-utility studies. Medline, Embase, SciSearch, Cochrane, and 9 other databases were searched from 2000 through April 2013 (including update) for full-text publications. The quality of the studies was assessed via the validated Quality of Health Economic Studies (QHES) instrument. Results: Nineteen studies (including update) involving the MoAb bevacizumab and the Tyrosine-kinase inhibitors erlotinib and gefitinib met all inclusion criteria. The majority of studies analyzed the CE of first-line maintenance and second-line treatment with erlotinib. Five studies dealt with bevacizumab in first-line regimes. Gefitinib and pharmacogenomic profiling were each covered by only two studies. Furthermore, the available evidence was of only fair quality. Conclusion: First-line maintenance treatment with erlotinib compared to Best Supportive Care (BSC) can be considered cost-effective. In comparison to docetaxel, erlotinib is likely to be cost-effective in subsequent treatment regimens as well. The insights for bevacizumab are miscellaneous. There are findings that gefitinib is cost-effective in first- and second-line treatment, however, based on only two studies. The role of pharmacogenomic testing needs to be evaluated. Therefore, future research should improve the available evidence and consider pharmacogenomic profiling as specified by the European Medicines Agency. Upcoming agents like crizotinib and afatinib need to be analyzed as well. eng
dc.description.sponsorship BMBF
dc.language.iso eng
dc.publisher London : BioMed Central Ltd.
dc.relation.ispartofseries BMC Pulmonary Medicine 14(2014), Nr. 1
dc.rights CC BY 2.0
dc.rights.uri https://creativecommons.org/licenses/by/2.0/
dc.subject Afatinib eng
dc.subject Bevacizumab eng
dc.subject Cost-effectiveness analysis eng
dc.subject Cost-utility analysis eng
dc.subject Crizotinib eng
dc.subject Erlotinib eng
dc.subject Gefitinib eng
dc.subject Health economics eng
dc.subject Monoclonal antibody eng
dc.subject Non-small cell lung cancer eng
dc.subject Targeted therapy eng
dc.subject Tyrosine kinase inhibitors eng
dc.subject afatinib eng
dc.subject antineoplastic agent eng
dc.subject bevacizumab eng
dc.subject cetuximab eng
dc.subject crizotinib eng
dc.subject docetaxel eng
dc.subject erlotinib eng
dc.subject gefitinib eng
dc.subject pemetrexed eng
dc.subject advanced cancer eng
dc.subject Article eng
dc.subject cancer chemotherapy eng
dc.subject cancer combination chemotherapy eng
dc.subject cancer staging eng
dc.subject cost effectiveness analysis eng
dc.subject cost utility analysis eng
dc.subject data base eng
dc.subject drug cost eng
dc.subject drug efficacy eng
dc.subject economic aspect eng
dc.subject Embase eng
dc.subject follow up eng
dc.subject human eng
dc.subject Medline eng
dc.subject metastasis eng
dc.subject non small cell lung cancer eng
dc.subject overall survival eng
dc.subject patient care eng
dc.subject pharmacogenomics eng
dc.subject quality of health economic study questionnaire eng
dc.subject questionnaire eng
dc.subject SciSearch eng
dc.subject systematic review eng
dc.subject.ddc 610 | Medizin, Gesundheit ger
dc.title A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC)
dc.type article
dc.type Text
dc.relation.issn 1471-2466
dc.relation.doi http://dx.doi.org/10.1186/1471-2466-14-192
dc.bibliographicCitation.issue 1
dc.bibliographicCitation.volume 14
dc.bibliographicCitation.firstPage 192
dc.description.version publishedVersion
tib.accessRights frei zug�nglich

Files in this item

This item appears in the following Collection(s):

Show simple item record


Search the repository


My Account

Usage Statistics